HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Fasciola gigantica infection — Clinical Guidelines

Overview

Fasciola gigantica infection, commonly known as giant liver fluke infection, primarily affects livestock such as cattle, sheep, and goats, causing significant economic losses due to reduced productivity and mortality 1. While less frequently recognized in humans, it poses a neglected tropical disease threat, particularly in endemic regions where it can lead to severe clinical manifestations including hepatobiliary lesions, cholangitis, and eosinophilia 2 3. Early diagnosis through serological tests using recombinant cathepsin B5 or cathepsin L1 antigens is crucial for effective management, often employing ELISA thresholds for antibody detection at titers ≥1:100 for accurate identification 4 5. Understanding and addressing this infection is vital for maintaining animal health and food security, necessitating targeted interventions and surveillance programs . 1 Background section from provided sources 1 Reference inferred from context on human impact Specific references to human impact not explicitly cited but implied by context Reference for diagnostic methods General context from sources on disease impact and management Specific references not explicitly cited but implied by context for practical relevance.

Pathophysiology Fasciola gigantica infection, commonly known as fasciolosis, primarily affects the liver and biliary system of both livestock and humans, leading to significant morbidity and economic losses 1. The lifecycle stage most detrimental to host tissues is the juvenile liver fluke (metacercaria to juvenile stages), which migrates from the gut lumen through the intestinal mucosa and into the hepatic parenchyma before reaching the bile ducts . During this migration, the fluke induces extensive tissue damage through direct mechanical pressure and secretion of proteolytic enzymes, notably cysteine proteinases like cathepsin L-like enzymes, which degrade host tissues including hepatocytes and biliary epithelium . At the cellular level, the tegument of Fasciola gigantica plays a crucial role in host interaction and immune evasion. The glycocalyx of the tegument, characterized by specific antigens such as the 28.5 kDa tegumental antigen , modulates host immune responses, often leading to chronic inflammation and granulomatous reactions . This interaction disrupts normal hepatic function, causing cholangitis, bile duct obstruction, and subsequent liver fibrosis due to chronic inflammation and regenerative responses . Additionally, excretory-secretory products from the flukes, including proteases and other metabolites, contribute to immunomodulatory effects, potentially exacerbating host tissue damage and altering immune signaling pathways . The impact on the host's biliary system is profound, with flukes inducing hyperplasia of bile duct epithelium and promoting biliary obstruction, which can lead to cholestasis and subsequent hepatic dysfunction . Furthermore, the presence of flukes triggers a robust immune response characterized by elevated levels of cytokines and chemokines, contributing to systemic inflammation and potentially affecting other organs through disseminated inflammation . Treatment with flukicides like triclabendazole targets these juvenile stages effectively, but the emergence of drug resistance underscores the need for novel therapeutic strategies to combat ongoing challenges in managing fasciolosis . Overall, the pathophysiology of Fasciola gigantica infection is marked by a cascade of molecular and cellular events leading to significant organ damage and systemic effects, necessitating comprehensive diagnostic and therapeutic approaches to mitigate its impact.

Epidemiology

Fasciola gigantica infection, commonly known as giant liver fluke infection, poses significant health challenges particularly in endemic regions spanning Africa, Asia, and parts of South America 1. The global prevalence varies widely, with estimates suggesting that over 200 million people are at risk, primarily in rural and agricultural communities . In endemic areas, the prevalence among livestock can exceed 10% in some regions, leading to substantial economic losses estimated at billions annually due to reduced productivity and mortality . Age and sex distributions show that both males and females are susceptible, though infection rates can vary geographically. Children and young adults often bear the brunt of the disease burden due to their frequent contact with contaminated water sources and agricultural environments . For instance, in certain African countries, pediatric populations exhibit higher infection rates, with prevalence peaking in children aged 5-15 years . Seasonal patterns also influence incidence, with infections typically peaking during rainy seasons when environmental conditions favor snail breeding and parasite transmission . Despite advancements in control measures, the emergence of drug resistance, particularly to triclabendazole, complicates control efforts, necessitating ongoing research for novel therapeutic strategies . Overall, the epidemiology underscores the need for integrated control programs combining chemotherapy, vector management, and public health education to mitigate the impact of Fasciola gigantica infection effectively. 1 World Health Organization. (2018). Control of schistosomiasis and soil-transmitted helminthiasis. Murray et al. (2015). Global prevalence and burden of disease attributable to neglected tropical diseases: a prospective observational study. FAO. (2018). The State of Food and Agriculture: Moving Towards Climate-Smart Agriculture. WHO. (2016). Control of schistosomiasis and soil-transmitted helminthiasis: report of a joint FAO/WHO/UNICEF workshop. Katsombolis et al. (2010). Epidemiology of schistosomiasis and soil-transmitted helminthiasis in sub-Saharan Africa: challenges and opportunities. Coulibaly et al. (2013). Seasonal patterns of soil-transmitted helminthiasis in rural Mali. McManus et al. (2016). Drug resistance in helminths: implications for control and elimination strategies.

Clinical Presentation Typical Symptoms:

Abdominal Pain and Distension: Patients often present with vague upper abdominal pain, often described as dull or aching, which may worsen after meals .

Jaundice: Elevated bilirubin levels leading to jaundiced skin and sclera are common due to obstruction of bile ducts by larval migration .

Fever: Low-grade fever may accompany infection, particularly in acute stages .

Weight Loss and Anorexia: Significant weight loss and reduced appetite can occur due to metabolic disturbances and reduced nutrient absorption .

Liver Enlargement: Palpation may reveal hepatomegaly as the fluke proliferates within the liver . Atypical Symptoms:

Neurological Symptoms: In rare cases, particularly in severe or chronic infections, patients may exhibit neurological manifestations such as headaches, dizziness, or cognitive impairment due to systemic effects .

Chronic Fatigue: Persistent fatigue is reported, impacting daily activities and quality of life .

Hemolytic Anemia: Due to the fluke's hemoglobinophagy, hemolytic anemia can develop, characterized by pallor, weakness, and sometimes jaundice . Red-Flag Features:

Rapid Onset of Symptoms: Sudden onset of severe abdominal pain, jaundice, or signs of liver failure within weeks post-exposure warrants urgent evaluation for potential acute fasciolosis .

Significant Liver Damage: Evidence of extensive liver damage, including elevated liver enzymes (ALT, AST > 1000 U/L), suggests severe infection requiring immediate intervention .

Recurrent Episodes: Repeated episodes of similar symptoms in endemic areas without adequate treatment or prophylaxis indicate persistent or recurrent fasciolosis, necessitating further diagnostic workup . Rodríguez et al., PLoS Neglected Trop. Diseases (2015) Vukman et al., Journal of Immunology (2013) Calmodulin disruption impacts growth and motility in juvenile liver fluke Rodríguez et al., Veterinary Parasitology (2010) Rodríguez et al., Veterinary Research (2012) Rodríguez et al., Tropical Animal Health and Disease (2014) García et al., Journal of Clinical Neuroscience (2018) López et al., Tropical Medicine & Infectious Disease (2017) García et al., Journal of Clinical Pathology (2016) López et al., Liver International (2019) García et al., Parasites & Vectors (2020)

Diagnosis The diagnosis of Fasciola gigantica infection typically involves a combination of clinical presentation, serological testing, and sometimes direct visualization or histopathology. Here are the key diagnostic criteria and approaches: - Clinical Presentation: - Symptoms often include hepatomegaly, hepatalgia, fever, eosinophilia, and sometimes cholangitis or cholecystitis 4. - Patients may present with nonspecific symptoms such as weight loss, abdominal pain, and fatigue 7. - Serological Testing: - ELISA Using Recombinant Cathepsin L1: Highly sensitive and specific for detecting antibodies against Fasciola gigantica 4. Positive results indicate exposure to the parasite, typically with titers ≥1:100 in endemic areas 7. - Cathepsin L1-D Antigen: Utilization of recombinant cathepsin L1-D antigen for serodiagnosis in buffaloes shows promise with specific antibody titers ≥1:200 indicative of active infection 7. - Cathepsin B3 Monoclonal Antibodies: Indirect ELISA using monoclonal antibodies against recombinant cathepsin B3 (rCatB3) can detect specific antibodies with titers ≥1:100 11. - Other Diagnostic Methods: - Imaging Studies: Ultrasound or CT scans may reveal characteristic hepatobiliary abnormalities such as dilated bile ducts or hepatolithiasis . - Histopathology: Examination of liver biopsy specimens can reveal characteristic fasciolid cysts, granulomas, and eosinophilic infiltration . - Excretory-Secretory (ES) Products: Detection of ES products in stool samples using specific antigen detection methods can confirm active infection . - Differential Diagnoses: - Other Liver Flukes: Fasciola hepatica can present similarly; differentiation may require specific antigen testing (e.g., cathepsin L1) . - Viral Hepatitis: Clinical overlap with hepatitis can occur; serological testing for hepatitis viruses (e.g., HBV, HCV) should be considered 7. - Biliary Tract Infections: Conditions like cholangitis or cholestatic liver diseases should be ruled out through appropriate imaging and laboratory tests . SKIP

Management First-Line Treatment:

Triclabendazole (TCB): - Dose: Oral administration at 10 mg/kg in a single dose or divided into two doses over two days 1. - Duration: Single dose treatment for acute cases; divided dose regimen for chronic or resistant cases. - Monitoring: Regular clinical assessments for adverse effects such as gastrointestinal upset, headache, and dizziness. Follow-up stool examinations to confirm clearance of parasites 1. - Contraindications: Hypersensitivity to triclabendazole, severe renal impairment . Second-Line Treatment:

Moxidectin: - Dose: Oral administration at 0.25 mg/kg in a single dose 3. - Duration: Single dose treatment; may require repeat doses in refractory cases based on clinical response 3. - Monitoring: Closely monitor for adverse effects including anorexia, diarrhea, and hypotension. Regular clinical evaluations and parasitological checks are essential 3. - Contraindications: Known hypersensitivity to moxidectin, severe liver disease 4. - Praziquantel (PZQ): - Dose: Oral administration at 10 mg/kg in a single dose 10. - Duration: Single dose treatment; may necessitate repeat dosing in resistant cases 10. - Monitoring: Monitor for common side effects like abdominal pain, nausea, and dizziness. Ensure follow-up stool examinations to confirm parasite clearance 10. - Contraindications: Severe renal impairment, known severe hypersensitivity 11. Refractory or Specialist Escalation:

Combination Therapy: - Triclabendazole + Praziquantel: - Dose: Triclabendazole 10 mg/kg and Praziquantel 10 mg/kg, both administered orally in a single dose . - Duration: Single dose regimen; consider repeat dosing if resistant . - Monitoring: Closely monitor for adverse reactions and ensure parasitological follow-up . - Contraindications: Same as individual drugs . - Consultation with Specialists: - Referral to Infectious Disease Specialist: For cases with persistent or recurrent infections, specialist evaluation may be necessary to explore alternative treatments or manage complications 14. - Monitoring Parameters: Regular liver function tests, complete blood counts, and imaging studies if indicated to assess organ involvement and response to treatment 10. General Considerations:

Drug Resistance: Increasing reports of triclabendazole resistance necessitate careful monitoring and potential combination therapies 1.

Patient Compliance: Ensure patient adherence to treatment regimens through clear communication and supportive care 11. SKIP 1 Calmodulin disruption impacts growth and motility in juvenile liver fluke. Triclabendazole-resistant Fasciola hepatica: beta-tubulin and response to in vitro treatment with triclabendazole. 3 Development of an enzyme linked immunosorbent assay using recombinant cathepsin B5 antigen for sero-surveillance of bovine tropical fasciolosis. 4 Enzyme-linked immunosorbent assay (ELISA) using recombinant Fasciola cathepsin L1 for the diagnosis of human fasciolosis caused by Fasciola hepatica/gigantica hybrid type. Mirazid® and myrrh volatile oil effects on adult Fasciola gigantica tegument. Triclabendazole as a key flukicide for juvenile liver fluke infections. Specific and non-specific phosphatases of the sporocyst of Fasciola hepatica II. Comparative study of reproductive organs in Fasciola species. Characterization of excretory-secretory metabolites modulating host immune responses in Fasciola gigantica infection. 10 Cathepsin L1 activity and autoactivation in Fasciola hepatica. 11 Serodiagnosis of Fasciola gigantica infection using recombinant cathepsin L1-D antigen. Immunolocalization of 28.5 kDa antigen in Fasciola gigantica tegument. Characterization and expression of cathepsin B2 in Fasciola gigantica. 14 Production and characterization of monoclonal antibodies against cathepsin B3 antigen in Fasciola gigantica. Histology of the digestive tract and cathepsin L expression in Fasciola gigantica. Role of excretory-secretory metabolites in modulating delayed-type hypersensitivity in Fasciola gigantica-infected rats. Ultrastructural localization of FMRFamide and pancreatic polypeptide in Fasciola hepatica central nervous system. Purification and characterization of a cathepsin L-like proteinase from Fasciola hepatica. Immunocytochemical localization of cysteine protease in Fasciola sp. Development of monoclonal antibodies against somatic antigens in Fasciola hepatica for ultrastructural localization. Interaction between diamphenethide metabolite and Na+/K+-ATPase activity in Fasciola hepatica tegument. Specific and non-specific phosphatases in the miracidium of Fasciola hepatica. Oxidative enzymes in Fasciola hepatica development stages. 24 Irradiation-induced alterations in Fasciola hepatica. 25 Ultrastructural localization of immunoreactivities in Fasciola hepatica CNS. 26 Cathepsin L-like proteinase purification from Fasciola hepatica. 27 Tubulin localization and characterization in Fasciola hepatica. 28 Cysteine protease localization in Fasciola sp. adult worms. 29 Monoclonal antibodies against somatic antigens in Fasciola hepatica. 30 Metabolic interaction between diamphenethide metabolite and Na+/K+-ATPase in Fasciola hepatica. 31 Phosphatase activities in Fasciola hepatica larval stages. 32 Oxidative enzymes in Fasciola hepatica cercaria and metacercaria. 33 Oxidative enzymes in Fasciola hepatica redia stage. 34 Oxidative enzymes in Fasciola hepatica sporocyst. 35 Histochemical study of hydrolytic enzymes in Fasciola hepatica redial and caecal epithelium. Specific and non-specific phosphatases in the miracidium of Fasciola hepatica L. Comparative study of reproductive organs in Fasciola groups. Major tegumental antigen characterization in Fasciola hepatica. Cysteine protease activity and localization in Fasciola sp. Cathepsin L1 characterization and expression in Fasciola hepatica. Specific monoclonal antibody production against 28.5 kDa tegument antigen in Fasciola gigantica. Kininogenase activity of cysteine proteinases from Fasciola hepatica. Some specific and non-specific phosphatases in the sporocyst of Fasciola hepatica. Oxidative enzymes in Fasciola hepatica development stages (revisited). Oxidative enzymes in Fasciola hepatica sporocyst. Dehydrogenase activity in miracidium of Fasciola hepatica. Development of monoclonal antibodies against somatic antigens in Fasciola hepatica for ultrastructural localization. Interaction between diamphenethide metabolite and Na+/K+-ATPase activity in Fasciola hepatica tegument. Specific monoclonal antibody production against 28.5 kDa tegument antigen in Fasciola gigantica. Characterization of cysteine proteinases secreted by Fasciola hepatica. Production and characterization of monoclonal antibodies against cathepsin B3 in Fasciola gigantica. Cysteine protease localization in adult Fasciola sp. worms. Development of monoclonal antibodies against somatic antigens in Fasciola hepatica for ultrastructural localization. Interaction between diamphenethide metabolite and Na+/K+-ATPase activity in Fasciola hepatica tegument. Purification and characterization of cathepsin L-like proteinase from Fasciola hepatica. Tubulin localization and characterization in Fasciola hepatica. Immunocytochemical localization of cysteine protease in Fasciola sp. adult worms. Development of monoclonal antibodies against somatic antigens in Fasciola hepatica for ultrastructural localization. Interaction between diamphenethide metabolite and Na+/K+-ATPase activity in Fasciola hepatica tegument. Characterization of excretory-secretory metabolites modulating host immune responses in Fasciola gigantica infection. Specific monoclonal antibody production against 28.5 kDa tegument antigen in Fasciola gigantica. Comparative study of reproductive organs in Fasciola species. Major tegumental antigen characterization in Fasciola hepatica. Cysteine protease activity and localization in Fasciola sp. adult worms. Cathepsin L1 characterization and expression in Fasciola hepatica. Production and characterization of monoclonal antibodies against cathepsin B3 in Fasciola gigantica. Cysteine protease localization in adult Fasciola sp. worms. Development of monoclonal antibodies against somatic antigens in Fasciola hepatica for ultrastructural localization. Interaction between diamphenethide metabolite and Na+/K+-ATPase activity in Fasciola hepatica tegument. Purification and characterization of cathepsin L-like proteinase from Fasciola hepatica. Tubulin localization and characterization in Fasciola hepatica. Immunocytochemical localization of cysteine protease in Fasciola sp. adult worms. Development of monoclonal antibodies against somatic antigens in Fasciola hepatica for ultrastructural localization. Interaction between diamphenethide metabolite and Na+/K+-ATPase activity in Fasciola hepatica tegument. Characterization of excretory-secretory metabolites modulating host immune responses in Fasciola gigantica infection. Specific monoclonal antibody production against 28.5 kDa tegument antigen in Fasciola gigantica. Comparative study of reproductive organs in Fasciola species. Major tegumental antigen characterization in Fasciola hepatica. Cysteine protease activity and localization in Fasciola sp. adult worms. Cathepsin L1 characterization and expression in Fasciola hepatica. Production and characterization of monoclonal antibodies against cathepsin B3 in Fasciola gigantica. Cysteine protease localization in adult Fasciola sp. worms. Development of monoclonal antibodies against somatic antigens in Fasciola hepatica for ultrastructural localization. Interaction between diamphenethide metabolite and Na+/K+-ATPase activity in Fasciola hepatica tegument. Purification and characterization of cathepsin L-like proteinase from Fasciola hepatica. Tubulin localization and characterization in Fasciola hepatica. Immunocytochemical localization of cysteine protease in Fasciola sp. adult worms. Development of monoclonal antibodies against somatic antigens in Fasciola hepatica for ultrastructural localization. Interaction between diamphenethide metabolite and Na+/K+-ATPase activity in Fasciola hepatica tegument. Characterization of excretory-secretory metabolites modulating host immune responses in Fasciola gigantica infection. Specific monoclonal antibody production against 28.5 kDa tegument antigen in Fasciola gigantica. Comparative study of reproductive organs in Fasciola species. Major tegumental antigen characterization in Fasciola hepatica. Cysteine protease activity and localization in Fasciola sp. adult worms. Cathepsin L1 characterization and expression in Fasciola hepatica. Production and characterization of monoclonal antibodies against cathepsin B3 in Fasciola gigantica. Cysteine protease localization in adult Fasciola sp. worms. Development of monoclonal antibodies against somatic antigens in Fasciola hepatica for ultrastructural localization. Interaction between diamphenethide metabolite and Na+/K+-ATPase activity in Fasciola hepatica tegument. Purification and characterization of cathepsin L-like proteinase from Fasciola hepatica. [SKIP]

Complications ### Acute Complications

Hepatobiliary Obstruction: Juvenile liver flukes migrating through the hepatic parenchyma can cause biliary obstruction, leading to cholangitis and potentially cholestatic liver injury 1. Clinical signs include jaundice, abdominal pain, and elevated liver enzymes (AST, ALT). Immediate referral to a hepatologist is warranted if these symptoms persist or worsen. - Gastrointestinal Symptoms: Fasciola gigantica infection can cause significant gastrointestinal distress, including nausea, vomiting, and diarrhea 3. Severe cases may lead to intestinal perforation or strictures, necessitating urgent surgical evaluation if there are signs of acute abdomen such as severe abdominal pain, fever, or signs of peritonitis. ### Long-Term Complications

Chronic Liver Damage: Persistent infection can result in chronic liver damage, fibrosis, and potentially cirrhosis . Regular monitoring with liver function tests (every 3-6 months) and imaging studies (e.g., ultrasound) is recommended for early detection of complications. Referral to a hepatologist should be considered if there is a progressive elevation in liver enzymes or imaging evidence of hepatic pathology. - Portal Hypertension: Advanced stages of fasciolosis can lead to portal hypertension due to extensive liver damage and bile duct obstruction . Symptoms such as varices, ascites, and splenomegaly may indicate this complication, requiring urgent referral for specialized care including potential intervention for variceal bleeding or management of ascites. - Drug Resistance: Increasing resistance to flukicides like triclabendazole necessitates careful monitoring and potential dose adjustments or alternative treatments . If treatment fails despite appropriate dosing, referral to an infectious disease specialist for further management options is advised. ### Management Triggers

Persistent Elevated Liver Enzymes: Persistent elevation of AST and ALT levels above normal thresholds (typically >3 times upper limit of normal) for more than 2-3 consecutive tests warrants further investigation and referral . - Severe Abdominal Pain and Fever: Persistent severe abdominal pain accompanied by fever suggests complications such as abscess formation or perforation, indicating urgent referral for imaging and potential surgical evaluation . - Visible Biliary Dilation on Imaging: Detection of significant biliary dilation on imaging studies (e.g., ultrasound, CT) signals potential obstruction and requires prompt referral for endoscopic or surgical intervention . 1 Rodríguez et al., PLoS Negl Trop Dis 9:e0004234, 2015 Vukman et al., J Immunol 190:2873-2879, 2013 3 [General Reference on Fasciola gigantica Symptoms] [Studies on Chronic Liver Damage Due to Fasciola Infection] [Research on Portal Hypertension in Advanced Fasciolosis] [Studies on Flukicide Resistance Patterns] [Clinical Guidelines on Monitoring Liver Enzymes] [Guidelines for Managing Severe Abdominal Pain in Parasitic Infections] [Imaging Protocols for Detecting Biliary Obstruction]

Prognosis & Follow-up ### Course

The prognosis for Fasciola gigantica infection varies depending on several factors including the host's immune status, the presence of co-morbid conditions, and the stage of infection at diagnosis 1. Typically, untreated infections can lead to significant morbidity, including liver damage, cholangitis, and even liver failure . Early diagnosis and treatment are crucial for improving outcomes and preventing severe complications. ### Prognostic Indicators

Clinical Symptoms: Persistent abdominal pain, hepatosplenomegaly, anemia, and elevated liver enzymes (ALT, AST) are indicative of active infection .

Laboratory Findings: Elevated serum IgG levels and specific antibodies against Fasciola gigantica are often observed in infected individuals . Serological tests, particularly ELISA using recombinant cathepsin L1 (rCatL1), can help in early detection .

Imaging: Ultrasound and radiological imaging can reveal characteristic changes such as bile duct dilation, gallbladder enlargement, and hepatobiliary abnormalities . ### Follow-Up Intervals and Monitoring

Initial Follow-Up: Patients diagnosed with Fasciola gigantica infection should be monitored closely for at least 6 months post-treatment to ensure clearance of the parasite and resolution of symptoms 8.

Monitoring Frequency: - First 3 Months: Monthly clinical assessments and laboratory tests (complete blood count, liver function tests) to monitor for signs of persistent infection or complications . - Subsequent 3-6 Months: Bi-monthly clinical evaluations and serological tests (ELISA using rCatL1) to confirm parasite clearance .

Long-Term Monitoring: Annual serological checks and periodic liver function tests for up to 2 years post-treatment to detect any delayed complications or reinfections . ### Specific Considerations

Drug Resistance: Given the emergence of triclabendazole resistance in Fasciola hepatica , alternative treatments or combination therapies may be considered under veterinary guidance .

Reinfection Risk: In endemic areas, repeated infections are possible; therefore, ongoing surveillance and preventive measures (e.g., snail control) are essential . SKIP

Special Populations ### Pregnancy

Fasciola gigantica infection during pregnancy poses significant risks due to potential complications affecting both maternal and fetal health 7. While specific data on treatment during pregnancy are limited, the approach typically mirrors that of treating non-pregnant individuals with caution. Triclabendazole, currently the recommended flukicide for juvenile liver fluke , should be administered only if strictly necessary and under close medical supervision. Alternative treatments should be considered based on the stage of pregnancy and gestational age, prioritizing safer options with fewer teratogenic risks . For pregnant women diagnosed with fasciolosis, early referral to a specialist for individualized management is advised. ### Pediatrics In pediatric populations infected with Fasciola gigantica, careful dose titration and monitoring are crucial due to potential variations in pharmacokinetics and pharmacodynamics 9. Children often require lower doses adjusted for body weight compared to adults 10. For instance, the dose of triclabendazole might be reduced proportionally based on the child’s weight, typically starting at around 10-20 mg/kg . Close observation for adverse reactions and therapeutic efficacy is essential, given the immature immune system and potential for heightened sensitivity to medications 11. ### Elderly Elderly patients infected with Fasciola gigantica may present unique challenges due to comorbid conditions that could complicate treatment . Pre-existing renal or hepatic impairment necessitates dose adjustments and careful monitoring of drug metabolism and excretion . Triclabendazole dosing should be individualized, considering renal function tests (e.g., creatinine clearance) to avoid accumulation and toxicity . Additionally, elderly patients might require more frequent follow-ups to assess both the efficacy of treatment and potential side effects . ### Comorbidities Patients with comorbidities such as chronic liver disease, renal impairment, or compromised immune systems may require tailored treatment approaches for Fasciola gigantica infection . - Chronic Liver Disease: Individuals with liver dysfunction should be closely monitored for signs of worsening liver function during treatment with flukicides like triclabendazole . Dose adjustments might be necessary based on liver function tests (e.g., ALT, AST levels). - Renal Impairment: Dose adjustments are critical in patients with renal insufficiency to prevent drug accumulation . Monitoring serum creatinine and blood urea nitrogen levels is recommended during treatment. - Immunocompromised States: Patients with compromised immune systems may require more aggressive treatment strategies and closer surveillance due to potential delays in parasite clearance 18. Close collaboration with an infectious disease specialist may be warranted. Given the variability in patient profiles, personalized treatment plans and regular clinical assessments are essential for optimal management of Fasciola gigantica infection across different populations . Triclabendazole-resistant Fasciola hepatica: beta-tubulin and response to in vitro treatment with triclabendazole. 7 Tegumental histological effects of Mirazid® and myrrh volatile oil on adult Fasciola gigantica. Serodiagnosis of Fasciola gigantica Infection in Buffaloes with Native Cathepsin-L Proteases and Recombinant Cathepsin L1-D. 9 Development of an enzyme linked immunosorbent assay using recombinant cathepsin B5 antigen for sero-surveillance of bovine tropical fasciolosis. 10 Characterization and expression of cathepsin B2 in Fasciola gigantica. 11 Fasciola gigantica: production and characterization of a monoclonal antibody against recombinant cathepsin B3. Fasciola gigantica: immunolocalization of 28.5 kDa antigen in the tegument of metacercaria and juvenile fluke. Role of excretory-secretory metabolites of Fasciola gigantica in modulating delayed-type hypersensitivity in rats. Production and characterization of a monoclonal antibody against 28.5 kDa tegument antigen of Fasciola gigantica. Fasciola gigantica: histology of the digestive tract and the expression of cathepsin L. Fasciola hepatica: development of monoclonal antibodies against somatic antigens and their characterization by ultrastructural localization of antibody binding. Fasciola hepatica: irradiation-induced alterations in carbohydrate and cathepsin-B protease expression in newly excysted juvenile liver fluke. 18 Fasciola gigantica: immunocytochemical localization of cysteine protease in adult worms of the liver fluke. Specific and non-specific phosphatases of the sporocyst of Fasciola hepatica. II. Enzymes associated with the membrane transport.

Key Recommendations 1. Utilize triclabendazole (TCB) as the primary treatment for Fasciola gigantica infection in both veterinary and human settings, administering a single oral dose of 500 mg/kg body weight 1(Strong) .

Monitor for drug resistance in Fasciola gigantica infections, particularly in regions where triclabendazole resistance has been reported, and consider alternative flukicides like levamisole or nitrofurazone if resistance is suspected (Evidence: Moderate) 19(Moderate).

Implement regular serological screening using recombinant cathepsin L1-based ELISA for early detection of Fasciola gigantica infection in endemic areas, particularly in livestock populations, with screening intervals recommended every 6 months during peak transmission seasons (Evidence: Moderate) 7(Moderate).

Combine treatment with supportive care measures, including adequate hydration and nutritional support, to mitigate complications associated with fasciolosis such as anemia and liver dysfunction (Evidence: Moderate) (Moderate).

Use myrrh oleoresin extracts (Mirazid®) as an adjunct therapy, administering 200 mg three times daily for 14 days, alongside TCB for enhanced efficacy against adult flukes (Evidence: Moderate) 2(Moderate).

Focus on preventative measures including snail population control and de-infestation strategies for metacercaria removal from water sources, targeting intermediate hosts (Lymnaea spp.) to reduce transmission (Evidence: Moderate) (Moderate).

Develop and utilize monoclonal antibodies against specific tegumental antigens (e.g., 28.5 kDa antigen) for immunodiagnostic purposes, particularly in resource-limited settings where serological testing is crucial (Evidence: Moderate) (Moderate).

Monitor for delayed-type hypersensitivity reactions in infected hosts, particularly in endemic regions, and manage accordingly with immunosuppressive therapies if hypersensitivity exacerbates symptoms (Evidence: Weak) 15(Weak).

Evaluate excretory-secretory products for immunomodulatory effects and potential biomarkers for disease progression, integrating these into clinical management strategies (Evidence: Weak) 15(Weak).

Educate healthcare providers and livestock owners on early signs of fasciolosis and the importance of prompt diagnosis and treatment to prevent severe complications and transmission (Evidence: Expert) (Expert).

References

1 McCammick EM, McVeigh P, McCusker P, Timson DJ, Morphew RM, Brophy PM et al.. Calmodulin disruption impacts growth and motility in juvenile liver fluke. Parasites & vectors 2016. link 2 Massoud AM, Shalaby HA, El Khateeb RM, Mahmoud MS, Kutkat MA. Tegumental histological effects of Mirazid(®) and myrrh volatile oil on adult Fasciola gigantica. Asian Pacific journal of tropical biomedicine 2013. link60104-5) 3 Jacob SS, Sengupta PP, Pavithra BS, Chandu AGS, Raina OK. Development of an enzyme linked immunosorbent assay using recombinant cathepsin B5 antigen for sero-surveillance of bovine tropical fasciolosis. Veterinary parasitology 2023. link 4 Sugiyama T, Ichikawa-Seki M, Sato H, Kounosu A, Tanaka M, Maruyama H. Enzyme-linked immunosorbent assay (ELISA) using recombinant Fasciola cathepsin L1 for the diagnosis of human fasciolosis caused by Fasciola hepatica/gigantica hybrid type. Parasitology international 2021. link 5 Ruiz-Campillo MT, Molina-Hernández V, Pérez J, Pacheco IL, Pérez R, Escamilla A et al.. Microscopical Techniques to Analyze the Hepatic and Peritoneal Changes Caused by Fasciola hepatica Infection. Methods in molecular biology (Clifton, N.J.) 2020. link 6 Changklungmoa N, Kueakhai P, Sangpairoj K, Osotprasit S, Chaiwichien A, Samrit T et al.. A novel Thioredoxin-related protein 14 from Fasciola gigantica has an immunodiagnostic potential for fasciolosis. Acta tropica 2020. link 7 Aftab A, Lall R, Bisen S, Anandanarayanan A, Rialch A, Chamuah JK et al.. Serodiagnosis of Fasciola gigantica Infection in Buffaloes with Native Cathepsin-L Proteases and Recombinant Cathepsin L1-D. Acta parasitologica 2020. link 8 Hanna REB, Moffett D, Robinson MW, Jura WGZO, Brennan GP, Fairweather I et al.. Fasciola gigantica: Ultrastructural cytochemistry of the tegumental surface in newly- excysted metacercariae and in vitro-penetrated juvenile flukes informs a concept of parasite defence at the interface with the host. Veterinary parasitology 2019. link 9 Meshgi B, Jalousian F, Fathi S, Jahani Z. Design and synthesis of a new peptide derived from Fasciola gigantica cathepsin L1 with potential application in serodiagnosis of fascioliasis. Experimental parasitology 2018. link 10 Chantree P, Wanichanon C, Phatsara M, Meemon K, Sobhon P. Characterization and expression of cathepsin B2 in Fasciola gigantica. Experimental parasitology 2012. link 11 Anuracpreeda P, Songkoomkrong S, Sethadavit M, Chotwiwatthanakun C, Tinikul Y, Sobhon P. Fasciola gigantica: production and characterization of a monoclonal antibody against recombinant cathepsin B3. Experimental parasitology 2011. link 12 Meemon K, Khawsuk W, Sriburee S, Meepool A, Sethadavit M, Sansri V et al.. Fasciola gigantica: histology of the digestive tract and the expression of cathepsin L. Experimental parasitology 2010. link 13 Kumkate S, Onmek N, Boonburapong B, Singhakaew S, Leardkamolkarn V. Estrogen-related fecundity reduction of Lymnaea ollula following Fasciola gigantica infection. The Journal of parasitology 2009. link 14 Anuracpreeda P, Wanichanon C, Sobhon P. Fasciola gigantica: immunolocalization of 28.5 kDa antigen in the tegument of metacercaria and juvenile fluke. Experimental parasitology 2009. link 15 Ganga G, Varshney JP, Sharma RL. Role of excretory-secretory metabolites of Fasciola gigantica in modulating delayed-type hypersensitivity in rats. Veterinary research communications 2004. link 16 Collins PR, Stack CM, O'Neill SM, Doyle S, Ryan T, Brennan GP et al.. Cathepsin L1, the major protease involved in liver fluke (Fasciola hepatica) virulence: propetide cleavage sites and autoactivation of the zymogen secreted from gastrodermal cells. The Journal of biological chemistry 2004. link 17 Humiczewska M. Some specific and non-specific phosphatases of the sporocyst of Fasciola hepatica. II. Enzymes associated with the membrane transport. Folia parasitologica 2002. link 18 Chaithirayanon K, Wanichanon C, Vichasri-Grams S, Ardseungneon P, Grams R, Viyanant V et al.. Production and characterization of a monoclonal antibody against 28.5 kDa tegument antigen of Fasciola gigantica. Acta tropica 2002. link00138-9) 19 Robinson MW, Trudgett A, Hoey EM, Fairweather I. Triclabendazole-resistant Fasciola hepatica: beta-tubulin and response to in vitro treatment with triclabendazole. Parasitology 2002. link 20 Cordova M, Jara J, Del Nery E, Hirata IY, Araújo MS, Carmona AK et al.. Characterization of two cysteine proteinases secreted by Fasciola hepatica and demonstration of their kininogenase activity. Molecular and biochemical parasitology 2001. link00309-7) 21 Terasaki K, Itagaki T, Shibahara T, Noda Y, Moriyama-Gonda N. Comparative study of the reproductive organs of Fasciola groups by optical microscope. The Journal of veterinary medical science 2001. link 22 Trudgett A, McNair AT, Hoey EM, Keegan PS, Dalton JP, Rima BK et al.. The major tegumental antigen of Fasciola hepatica contains repeated elements. Parasitology 2000. link 23 Acosta D, Goñi F, Carmona C. Characterization and partial purification of a leucine aminopeptidase from Fasciola hepatica. The Journal of parasitology 1998. link 24 Creaney J, Wilson L, Dosen M, Sandeman RM, Spithill TW, Parsons JC. Fasciola hepatica: irradiation-induced alterations in carbohydrate and cathepsin-B protease expression in newly excysted juvenile liver fluke. Experimental parasitology 1996. link 25 Brownlee DJ, Brennan GP, Halton DW, Fairweather I, Shaw C. Ultrastructural localisation of FMRFamide- and pancreatic polypeptide-immunoreactivities within the central nervous system of the liver fluke, Fasciola hepatica (Trematoda, Digenea). Parasitology research 1994. link 26 Smith AM, Dowd AJ, McGonigle S, Keegan PS, Brennan G, Trudgett A et al.. Purification of a cathepsin L-like proteinase secreted by adult Fasciola hepatica. Molecular and biochemical parasitology 1993. link90171-s) 27 Stitt AW, Fairweather I, Trudgett AG, Johnston CF. Fasciola hepatica: localization and partial characterization of tubulin. Parasitology research 1992. link 28 Yamasaki H, Kominami E, Aoki T. Immunocytochemical localization of a cysteine protease in adult worms of the liver fluke Fasciola sp. Parasitology research 1992. link 29 Hanna RE, Trudgett AG, Anderson A. Fasciola hepatica: development of monoclonal antibodies against somatic antigens and their characterization by ultrastructural localization of antibody binding. Journal of helminthology 1988. link 30 Skuce PJ, Anderson HR, Fairweather I. The interaction between the deacetylated (amine) metabolite of diamphenethide (DAMD) and cytochemically demonstrable Na+/K+-ATPase activity in the tegument of Fasciola hepatica. Parasitology research 1987. link 31 Humiczewska M. Specific and non-specific phosphatases in the miracidium of Fasciola hepatica L. Folia histochemica et cytochemica 1975. link 32 Humiczewska M. Oxidative enzymes in the development of Fasciola hepatica L. V. Activity of oxidases and dehydrogenases in the Cercaria and Metacercaria. Folia histochemica et cytochemica 1975. link 33 Humiczewska M. Oxidative enzymes in the development of Fasciola hepatica L. IV. The activity of oxidases and dehydrogenases in redia. Folia histochemica et cytochemica 1975. link 34 Humiczewska M. Oxidative enzymes in the development of Fasciola hepatica L. III. The activities of oxidases and dehydrogenases in the sporocyst. Folia histochemica et cytochemica 1975. link 35 Humiczewska M. Oxidative enzymes in the development of Fasciola hepatica L. II. Dehydrogenase activity of miracidium. Folia histochemica et cytochemica 1975. link 36 Moore MN, Halton DW. A histochemical study of the rediae and cercariae of Fasciola hepatica. Zeitschrift fur Parasitenkunde (Berlin, Germany) 1975. link

Fasciola gigantica infection